Hosted on MSN8mon
Lilly lifts sales forecast by $3 billion as weight-loss drug powers results
Eli Lilly raised its annual sales forecast by $3 billion on Thursday, driven by surging demand and ramped up manufacturing capacity for its popular weight-loss drug Zepbound, lifting its shares ...
pharmaphorum16d
Zepbound tops Wegovy in first head-to-head weight-loss trial
Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector, but has new data that could tip the balance in its favour. The results of the first head-to-head trial of ...